GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Onward Medical NV (STU:63E) » Definitions » Short-Term Debt

Onward Medical NV (STU:63E) Short-Term Debt : €0.00 Mil (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Onward Medical NV Short-Term Debt?

Onward Medical NV's Short-Term Debt for the quarter that ended in Dec. 2023 was €0.00 Mil.


Onward Medical NV Short-Term Debt Historical Data

The historical data trend for Onward Medical NV's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Onward Medical NV Short-Term Debt Chart

Onward Medical NV Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Short-Term Debt
Get a 7-Day Free Trial - - - - -

Onward Medical NV Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Onward Medical NV Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.


Onward Medical NV Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Onward Medical NV's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Onward Medical NV (STU:63E) Business Description

Traded in Other Exchanges
Address
High Tech Campus 32, Noord-Braban, Eindhoven, NH, NLD, NL-5656 AE
Onward Medical NV is a medical technology company developing and commercializing therapies to enable functional recovery for people with spinal cord injury. It has developed two programmable neurostimulation platforms: an implantable system, ARCIM, and a non-invasive, transcutaneous system, ARCEX. The company has selected the United states and four European markets: Germany, France, the UK and the Netherlands to create a customer base.

Onward Medical NV (STU:63E) Headlines

No Headlines